is glp 1 safe with kidney disease GLP-1 agonists in the treatment of chronic in type 2 diabetes and obesity GLP-1 Medications & Their Potential
Description
Consistency, not fragmentation, is what drives the 1522% body weight reductions seen in landmark trials
Heres why the location matters: visceral fat increases from 5-8% of total body fat in the premenopausal state to 15-20% of total body fat in the postmenopausal state
Side-effects are a concern for some
nor about replacing meals
Overall, if considering Saxenda for weight loss, understanding and monitoring potential side effects is crucial
The 2024 multi-society guidance shifted to continuation for most patients with targeted precautions for higher-risk patients
